Drug Interactions—A Review

Linnarsson, 1993, Drug interactions in primary health care. A retrospective database study and its implications for the design of a computerized decision support system, Scand J Prim Health Care, 11, 181, 10.3109/02813439308994827 Monaghan MS, Falls L, Olsen KM. Potential drug interactions with H2-receptor antagonists in intensive care unit patients. Hosp Pharm 1993;28:296-297, 300-305. Gaddis, 2002, Drug interactions in at-risk emergency department patients, Acad Emerg Med, 9, 1162, 10.1111/j.1553-2712.2002.tb01571.x Wallace, 2003, Lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers, J Clin Pharmacol, 43, 539, 10.1177/0091270003253399 In: Pfizer Labs. p. Vibramycin package insert. Neuhofel, 2002, Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction, J Clin Pharmacol, 42, 461, 10.1177/0091270002424013 Kato, 2002, Impairment of ciprofloxacin absorption by calcium polycarbophil, J Clin Pharmacol, 42, 806, 10.1177/009127002401102641 Wallace, 2003, Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers, J Clin Pharmacol, 43, 92, 10.1177/0091270002239711 Bauer, 1982, Interference of oral phenytoin absorption by continuous nasogastric feedings, Neurology, 32, 570, 10.1212/WNL.32.5.570 Faraji, 1998, Serum phenytoin levels of patients on gastrostomy tube feeding, J Neurosci Nurs, 30, 55, 10.1097/01376517-199802000-00001 Maynard, 1987, Phenytoin absorption from tube feedings, Arch Intern Med, 147, 1821, 10.1001/archinte.1987.00370100135022 Rodman, 1995, Phenytoin malabsorption after jejunostomy tube delivery, Pharmacotherapy, 15, 801, 10.1002/j.1875-9114.1995.tb02902.x Saklad, 1986, Interaction of oral phenytoin with enteral feedings, JPEN J Parenter Enteral Nutr, 10, 322, 10.1177/0148607186010003322 Sneed, 1988, Interference of oral phenytoin absorption by enteral tube feedings, Arch Phys Med Rehabil, 69, 682 La Humma, 2002, Pharmacogenetics, 55 Gheuens, 2000 Wells, 1994, Interactions of warfarin with drugs and food, Ann Intern Med, 121, 676, 10.7326/0003-4819-121-9-199411010-00009 Drug input and disposition. In: Mark H, Beers RB, editors. The Merck manual of diagnosis and therapy. 17th ed. Medical Services, USMEDSA, USHH; 2004. Shannon, 1997, Drug-drug interactions and the cytochrome P450 system: an update, Pediatr Emerg Care, 13, 350, 10.1097/00006565-199710000-00015 Kearns, 2003, Developmental pharmacology-drug disposition, action, and therapy in infants and children, N Engl J Med, 349, 1157, 10.1056/NEJMra035092 Weinshilboum, 2003, Inheritance and drug response, N Engl J Med, 348, 529, 10.1056/NEJMra020021 Alscher, 2003, Drug interaction of herbal tea containing St. John's wort with cyclosporine, Transpl Int, 16, 543, 10.1111/j.1432-2277.2003.tb00345.x Barone, 2000, Drug interaction between St. John's wort and cyclosporine, Ann Pharmacother, 34, 1013, 10.1345/aph.10088 Barone, 2001, Herbal supplements: a potential for drug interactions in transplant recipients, Transplantation, 71, 239, 10.1097/00007890-200101270-00012 Breidenbach, 2000, Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort (Hypericum perforatum), Transplantation, 69, 2229, 10.1097/00007890-200005270-00052 Izzo, 2004, Drug interactions with St. John's wort (Hypericum perforatum): a review of the clinical evidence, Int J Clin Pharmacol Ther, 42, 139, 10.5414/CPP42139 Karliova, 2000, Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation, J Hepatol, 33, 853, 10.1016/S0168-8278(00)80321-9 Markowitz, 2001, The emerging recognition of herb-drug interactions with a focus on St. John's wort (Hypericum perforatum), Psychopharmacol Bull, 35, 53 Moschella, 2001, Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation, Am J Kidney Dis, 38, 1105, 10.1053/ajkd.2001.28617 Zhou, 2003, Interactions of herbs with cytochrome P450, Drug Metab Rev, 35, 35, 10.1081/DMR-120018248 Zhou, 2004, Herbal modulation of P-glycoprotein, Drug Metab Rev, 36, 57, 10.1081/DMR-120028427 Cuzzolin, 2003, Patterns and perceptions of complementary/alternative medicine among paediatricians and patients' mothers: a review of the literature, Eur J Pediatr, 162, 820, 10.1007/s00431-003-1313-9 Lanski, 2003, Herbal therapy use in a pediatric emergency department population: expect the unexpected, Pediatrics, 111, 981, 10.1542/peds.111.5.981 Noonan, 2004, Herbal medication use in the pediatric surgical patient, J Pediatr Surg, 39, 500, 10.1016/j.jpedsurg.2003.11.017 Wilkinson, 2001, Pharmacokinetics Hazai, 2002, Reduction of toxic metabolite formation of acetaminophen, Biochem Biophys Res Commun, 291, 1089, 10.1006/bbrc.2002.6541 Watson Laboratories I. Probenicid package insert. 2003. Beorlegui, 2000, Potential interaction between methotrexate and omeprazole, Ann Pharmacother, 34, 1024, 10.1345/aph.19094 Reid, 1993, Impact of omeprazole on the plasma clearance of methotrexate, Cancer Chemother Pharmacol, 33, 82, 10.1007/BF00686028 Juurlink, 2004, Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study, N Engl J Med, 351, 543, 10.1056/NEJMoa040135 Scott, 2004 Svensson, 2003, Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study, BMJ, 327, 1141, 10.1136/bmj.327.7424.1141 Wrenger, 2003, Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases, BMJ, 327, 147, 10.1136/bmj.327.7407.147 Palmer, 2004, Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system, N Engl J Med, 351, 585, 10.1056/NEJMra035279 McMurray, 2004, Treatment of heart failure with spironolactone—trial and tribulations, N Engl J Med, 35, 526, 10.1056/NEJMp048144 Baldessarini, 2001, Drugs and the treatment of psychiatric disorders Rose, 2000, A hypertensive reaction induced by concurrent use of selegiline and dopamine, Ann Pharmacother, 34, 1020, 10.1345/aph.19221 Aga, 2003, Linezolid, a monoamine oxidase inhibiting antibiotic, and antidepressants, J Clin Psychiatry, 64, 609, 10.4088/JCP.v64n0518b French, 2003, Safety and tolerability of linezolid, J Antimicrob Chemother, 51, ii45, 10.1093/jac/dkg253 Hammerness, 2002, Linezolid: MAOI activity and potential drug interactions, Psychosomatics, 43, 248, 10.1176/appi.psy.43.3.248-a Hendershot, 2001, Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr, J Clin Pharmacol, 41, 563, 10.1177/00912700122010302 Thomas, 2004, Serotonin syndrome and linezolid, J Am Acad Child Adolesc Psychiatry, 43, 790, 10.1097/01.chi.0000128830.13997.aa Sproule, 1997, Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence, Clin Pharmacokinet, 33, 454, 10.2165/00003088-199733060-00004 Kehoe, 1998, Update on adverse reactions to SSRI antidepressants Muscettola, 1993, Persistent tardive dyskinesia: demographic and pharmacological risk factors, Acta Psychiatr Scand, 87, 29, 10.1111/j.1600-0447.1993.tb03326.x